Revenio Group Corporation: INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

Revenio Group Corporation, Stock Exchange Release, November 8, 2018 at 9:00

INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

Total of 50,856 new share subscriptions based on the company's 2015A stock options approved by the Board of Directors of Revenio Group Corporation on October 24, 2018, have been entered into the trade register today. The share subscription price under 2015A option rights was 8.23 EUR per share. The subscription period for 2015A options is May 31, 2017-May 31, 2019.

After these subscriptions, the number of Revenio Group Corporation's shares and votes will rise to 23,998,761. These increases were recorded in their entirety in the unrestricted shareholders' equity fund.

Revenio Group Corporation has applied for the listing of its new shares on the Nasdaq Helsinki in the same series as the company's existing shares. According to the current estimate, the new shares will be listed on November 9, 2018.

Revenio Group Corporation
Board of Directors

For further information, please contact:
Timo Hildén, CEO, tel.  +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media

www.revenio.fi 

The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2017, net sales of Revenio Group totaled MEUR 26.8, with an operating margin of 35.5%, excluding non-recurring expenses. Revenio Group Corporation is listed on Nasdaq Helsinki.

Subscribe